ODYSSEY ALTERNATIVE: Efficacy and safety of alirocumab versus ezetimibe, in patients with statin intolerance defined by placebo run-in and statin rechallenge arm

Patrick M. Moriarty¹, Paul D. Thompson², Christopher P. Cannon³, John R. Guyton⁴, Jean Bergeron⁵, Franklin J. Zieve⁶, Eric Bruckert⁷, Terry A. Jacobson⁸, Marie T. Baccara-Dinet⁹, Jian Zhao¹⁰, Yunling Du¹⁰, Robert Pordy¹¹, Daniel Gipe¹¹

¹Department of Internal Medicine, Division of Clinical Pharmacology, University of Kansas Medical Center, Kansas City, KS, USA; ²Hartford Hospital, Hartford, CT, USA; ³Harvard Clinical Research Institute, Boston, MA, USA; ⁴Duke University Medical Center, Durham, NC, USA; ⁵Clinique des Maladies Lipidiques de Québec Inc., Québec, Canada; ⁶McGuire VA Medical Center, Richmond, VA, USA; ⁷Hospitalier Pitié-Salpêtrière, Paris, France; ⁸Emory University, Atlanta, GA, USA; ⁹Sanofi, Montpellier, France; ¹⁰Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, USA; ¹¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

ClinicalTrials.gov identifier: NCT01709513 This study was funded by Sanofi and Regeneron Pharmaceuticals, Inc.



Statin Intolerance (SI): Limits Many Patients from Achieving LDL-C Goals


- SI: Inability to use statins for long-term reduction of lipids and/or CV risk because of significant symptoms and/or biomarker abnormalities that can be temporally attributed to the initiation or dose escalation of statins¹
- ~10–25% patients in clinical practice report SI^{2,3}
 - Cleveland Clinic
 - Myalgia was most common complaint
 - However, 63.2% patients with previous SI were able to tolerate daily statin therapy⁴

Large, well-controlled randomized trials of cholesterollowering drugs in statin intolerant patients are lacking⁵

- 1. Mancini GBJ et al. Can J Cardiol. 2013;29:1553–1568; 2. Bruckert E et al. Cardiovasc Drugs Ther. 2005;19:403–414.
- 3. Cohen JD et al. J Clin Lipidol. 2012;6:208–215. 4. Mampuya WM et al. Am Heart J. 2013;166:597–603.
- 5. Guyton JR et al. J Clin Lipidol. 2014;8:S72–S81.




ODYSSEY ALTERNATIVE Study Design



*Unable to tolerate at least two different statins, including one at the lowest dose, due to muscle-related symptoms

[†]4-week single-blind placebo run-in follows 2-week washout of statins, ezetimibe and red yeast rice. OLTP: Alirocumab open-label treatment period; W, Week.

Patient Disposition





Baseline Characteristics


	Alirocumab (N=126)	Ezetimibe (N=125)	Atorvastatin (N=63)
Age, years, mean (SD)	64.1 (9.0)	62.8 (10.1)	63.4 (8.9)
Male, %	55.6%	53.6%	55.6%
Race, white, %	92.9%	92.8%	98.4%
BMI, kg/m², mean (SD)	29.6 (6.6)	28.4 (4.9)	29.7 (5.4)
HeFH, %	11.1%	20.0%	12.7%
Hypertension, %	67.5%	61.6%	55.6%
Type 2 diabetes, %	28.6%	19.2%	23.8%
CHD history, %	50.8%	43.2%	44.4%
Current smoker, %	8.7%	4.0%	7.9%
LLT other than statin/ezetimibe	37.3%	44.0%	54.0%

Baseline Lipids


	Alirocumab (N=126)	Ezetimibe (N=125)	Atorvastatin (N=63)
LDL-C (calculated), mg/dL, mean (SD)	191.1 (72.7)	193.5 (70.9)	187.3 (59.5)
Non-HDL-C, mg/dL, mean (SD)	230.0 (80.4)	229.8 (82.7)	223.8 (64.8)
Apo B, mg/dL, mean (SD)	141.7 (39.5)	138.2 (37.4)	139.1 (34.7)
Lp(a), mg/dL, median (IQR)	18 (8:47)	14 (7:43)	12 (6:50)
Triglycerides, mg/dL, median (IQR)	164 (114:233)	140 (95:218)	158 (119:246)
HDL-C, mg/dL, mean (SD)	48.9 (15.3)	50.7 (14.1)	51.1 (12.5)
Apo A1, mg/dL, mean (SD)	149.4 (25.0)	150.0 (24.2)	154.2 (24.8)



Alirocumab Significantly Reduced LDL-C from Baseline to Week 24 versus Ezetimibe



Alirocumab Maintained LDL-C Reductions Week 4–24



Significantly More SI Patients Achieved Target LDL-C <70 or <100 mg/dL (depending on CV risk) with Alirocumab vs Ezetimibe

Goals: Very high-risk: LDL-C <70 mg/dL, High/moderate-risk: <100 mg/dL

ITT


60 60 Alirocumab 51% **Ezetimibe** 50 **50** % patientsreaching DL-C goal at Week 2 42% 40 **40** 30 30 20 20 ۵ 10 6% 10 4% 0 0 P<0.0001 P<0.0001

Baseline LDL-C levels (ITT): 191.1 and 194.2 mg/dL in alirocumab and ezetimibe arms. Baseline LDL-C levels (on-treatment): 188.8 and 195.3 mg/dL in alirocumab and ezetimibe arms.

ODYSSE

On-treatment

Significant Reductions in Secondary Lipid **Parameters at Week 24**



For Lp(a): Adjusted mean (SE) from robust regression with multiple imputation procedure.

Safety Analysis

Safety analysis from double-blind treatment period


% of patients	Alirocumab (N=126)	Ezetimibe (N=124)	Atorvastatin (N=63)
TEAEs [†]	82.5%	80.6%	85.7%
Treatment-emergent SAEs	9.5%	8.1%	11.1%
TEAEs leading to death	0	0	0
TEAEs leading to discontinuation	18.3%	25.0%	25.4%
Any skeletal-muscle related TEAE [‡]	32.5%	41.1%	46.0%
HR (95% CI) alirocumab vs comparator	-	0.71 (95% CI: 0.47 to 1.06)	0.61 (95% CI: 0.38 to 0.99)
<i>P</i> -value vs alirocumab [§]	-	0.096	0.042
Skeletal-muscle related TEAE leading to discontinuation	15.9%	20.2%	22.2%
HR (95% CI) alirocumab vs comparator	-	0.78 (95% CI: 0.43 to 1.41)	0.67 (95% CI: 0.34 to 1.32)
<i>P</i> -value vs alirocumab [§]	-	0.409	0.240

⁺TEAE (treatment emergent adverse event) period = time from first to last injection of study treatment + 70 days. SAE = serious adverse event.

[‡]Pre-defined category including myalgia, muscle spasms, muscular weakness, musculoskeletal stiffness, muscle fatigue. [§] Although not pre-planned analysis, the *P*-value is shown for descriptive purposes.

Fewer Skeletal Muscle AEs with Alirocumab than with Atorvastatin

Kaplan-Meier estimates for time to first skeletal muscle event[†]



[†]Pre-defined category including myalgia, muscle spasms, muscular weakness, musculoskeletal stiffness, muscle fatigue. ALI, alirocumab; ATV, atorvastatin, EZE, ezetimibe.



Safety Analysis: Additional AEs of Interest

Safety analysis from double-blind treatment period

% (n) of patients	Alirocumab (N=126)	Ezetimibe (N=124)	Atorvastatin (N=63)
Adjudicated CV events [†]	2.4% (n=3)	0.8% (n=1)	1.6% (n=1)
Ischemia-driven coronary revascularization procedure	2.4% (n=3)	0.8% (n=1)	1.6% (n=1)
Non-fatal MI	0.8% (n=1)	0	0
Injection-site reactions	4.8% (n=6)	4.8% (n=6)	1.6% (n=1)
Neurocognitive disorders	2.4% (n=3)	1.6% (n=2)	0
Creatine kinase >3x ULN, % (n/N)	2.4% (3/126)	1.6% (2/123)	4.8% (3/62)
Myositis*	0	0	1.6% (n=1)
ALT >3x ULN, % (n/N)	0	0	0

[†]Adjudicated CV events categories: CHD death, non-fatal MI, fatal and non-fatal ischemic stroke, unstable angina requiring hospitalization, congestive heart failure requiring hospitalization, ischemia-driven revascularization procedure (PCI, CABG). *Muscle symptoms with CK ≥3 x ULN and <10 x ULN. Patients can be reported as having more than one CV event. ALT, alanine transaminase; ULN, upper limit of normal.


Safety Analysis: TEAEs Occurring in ≥5% of Patients in Any Group

Safety analysis from double-blind treatment period

% (n) of patients	Alirocumab (N=126)	Ezetimibe (N=124)	Atorvastatin (N=63)
Myalgia	24.6 (31)	23.4 (29)	27.0 (17)
Nasopharyngitis	6.3 (8)	8.1 (10)	3.2 (2)
Arthralgia	5.6 (7)	7.3 (9)	7.9 (5)
Upper respiratory tract infection	5.6 (7)	4.0 (5)	3.2 (2)
Headache	4.8 (6)	4.8 (6)	6.3 (4)
Fatigue	4.8 (6)	3.2 (4)	7.9 (5)
Muscle spasms	4.0 (5)	7.3 (9)	11.1 (7)
Back pain	4.0 (5)	5.6 (7)	7.9 (5)
Paraesthesia	3.2 (4)	0	6.3 (4)
Vomiting	2.4 (3)	0.8 (1)	6.3 (4)
Muscular weakness	0.8 (1)	1.6 (2)	6.3 (4)



Patient Disposition – Open Label Treatment Period (OLTP)



⁺Dose ↑ from 75 mg to 150 mg Q2W at W36 based on the LDL-C level at W32 and the judgment of the investigator

Interim Safety Results from the Ongoing 3-Year OLTP

Safety analysis from start of OLTP up to 52 weeks

- 89.5% of randomized patients entered the OLTP (including 94% of those randomized to atorvastatin).
- All patients in OLTP receive alirocumab 75 mg Q2W (with dose increase possible to 150 mg Q2W after 12 weeks OLTP treatment).

	Alirocumab (N=281)
Mean (SD) exposure during OLTP (weeks)	13.9 (6.8)
Any TEAE	55.9% (n=157)
Myalgia	4.3% (n=12)
Muscle spasms	1.8% (n=5)
Musculoskeletal stiffness	0.7% (n=2)
TEAE leading to discontinuation	2.8% (n=8)
Myalgia (leading to discontinuation)	0.7% (n=2 [†])

[†]The two patients who discontinued due to myalgia originally came from the alirocumab and ezetimibe arms, respectively.

Safety Summary

ODYSSEY ALTERNATIVE and alirocumab safety across placebo-controlled studies

	ODYSSEY ALTERNATIVE				Pooled alirocumab	
	Tr	Double-blind Treatment Period		Open Label Treatment Period	Phase 2/3 placebo- controlled studies	
% of patients	Alirocumab (N=126)	Ezetimibe (N=124)	Atorvastatin (N=63)	Alirocumab (N=281)	Alirocumab (N=2476)	Placebo (N=1276)
Mean duration of treatment (weeks)	21.5	19.8	19.4	13.9	58.3	57.6
TEAEs [†]	82.5%	80.6%	85.7%	55.9%	75.8%	76.4%
TEAEs leading to discontinuation	18.3%	25.0%	25.4%	2.8%	5.3%	5.1%
Any skeletal-muscle related TEAE [‡]	32.5%	41.1%	46.0%	13.9%	15.1%	15.4%
Skeletal-muscle related TEAE leading to discontinuation	15.9%	20.2%	22.2%	1.4%	0.4%	0.5%

[†]TEAE period = time from first to last injection of study treatment + 70 days. [‡]Pre-defined category including myalgia, muscle spasms, muscular weakness, musculoskeletal stiffness, muscle fatigue.



Conclusions: ODYSSEY ALTERNATIVE

- In a population of statin intolerant patients with very high baseline LDL-C levels (~190 mg/dL):
 - Self-administered alirocumab produced significantly greater LDL-C reductions versus ezetimibe at Week 24 (LS mean difference of 30.4%)
 - Mean achieved LDL-C = 108.5 mg/dL at Week 24
 - 92 mg/dL on-treatment analysis
 - ~50% did not need dose increase to alirocumab 150 mg Q2W at Week 12
 - 42% of alirocumab patients achieved their LDL-C goals at Week 24
 - In this study, alirocumab was better tolerated than atorvastatin (HR ALI vs ATV = 0.61 (95% CI: 0.38 to 0.99), nominal P=0.042)
 - Fewer patients with skeletal muscle-related TEAEs (myalgia, muscle spasms, muscular weakness, musculoskeletal stiffness, and muscle fatigue) with alirocumab than with atorvastatin and ezetimibe

Fewer skeletal muscle events observed to date in the alirocumab OLTP compared with the main study

• Only two of 281 patients discontinued due to myalgia



Overview of the ODYSSEY Phase 3 Program

Fourteen global Phase 3 trials including >23 500 patients across >2000 study centres

HeFH population	HC in high CV-risk population		Additional populations
Add-on to max tolerated statin (± other LLT)	Add-on to max tolerated statin $(\pm \text{ other LLT})$		ODYSSEY MONO (NCT01644474; EFC11716)
ODYSSEY FH I (NCT01623115; EFC12492) LDL-C ≥70 mg/dL OR LDL-C ≥100 mg/dL n=486; 18 months	ODYSSEY COMBO I (NCT01644175; EFC11568) LDL-C ≥70 mg/dL OR LDL-C ≥100 mg/dL n=316; 12 months		Patients on no background LLTs LDL-C ≥100 mg/dL n=103; 6 months
ODYSSEY FH II (NCT01709500; CL1112) LDL-C ≥70 mg/dL OR LDL-C ≥100 mg/dL n=249; 18 months	[†] ODYSSEY COMBO II (NC LDL-C ≥70 mg/dL OR LDL n=720; 24 months	толение сомвот Толение сомвот Толение сомвот	ODYSSEY ALTERNATIVE (NCT01709513; CL1119) Patients with defined statin intolerance LDL-C ≥70 mg/dL OR LDL-C ≥100 mg/dL n=314; 6 months
ODYSSEY HIGH FH (NCT01617655; EFC12732) LDL-C ≥160 mg/dL n=107; 18 months		ODYSSEY CHOICE I (NCT019 LDL-C ≥70 mg/dL OR LDL-C n=700; 12 months	
ODYSSEY OLE (NCT01954394; LTS 13463) Open-label study for FH from EFC 12492, CL 1112, EFC 12732 or LTS 11717 n≥1000; 30 months			ODYSSEY CHOICE II (NCT02023879; EFC13786) Patients not treated with a statin LDL-C ≥70 mg/dL OR LDL-C ≥100 mg/dL n=200; 6 months
ODYSSEY LONG TERM (NCT0150) LDL-C ≥70 mg/dL n=2341; 18 months	7831; LTS11717)		ODYSSEY OPTIONS I (NCT01730040; CL1110) Patients not at goal on moderate-dose atorvastatin LDL-C ≥70 mg/dL OR LDL-C ≥100 mg/dL n=355; 6 months
	ODYSSEY OUTCOMES (N LDL-C ≥70 mg/dL n=18 000; 64 months	CT01663402; EFC11570)	ODYSSEY OPTIONS II (NCT01730053; CL1118) Patients not at goal on moderate-dose rosuvastatin LDL-C ≥70 mg/dL OR LDL-C ≥100 mg/dL n=305; 6 months

CODYS

[†]For ODYSSEY COMBO II other LLT not allowed at entry.

Thank You to All Principal Investigators and National Coordinators!

